LBA01-19 LONG-TERM EFFICACY AND SAFETY OF URO-902 (PVAX/ HSLO ) IN WOMEN WITH OVERACTIVE BLADDER AND URGE URINARY INCONTINENCE: FINAL RESULTS OF A PHASE 2A TRIAL

Autor: Kenneth M. Peters, Ekene A. Enemchukwu, Susan Kalota, Kaiser Robertson, Sijian Ge, Jingmei Lu, Hanh Badger, Salim Mujais

Publikováno v: Journal of Urology. 209

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e97529498d6695498b98e3e59bbb2dbd
https://doi.org/10.1097/ju.0000000000003360.19

Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results

Autor: Sheldon Freedman, James Bailen, Alan Hay, Frederick Snoy, Richard Levin, Mohamed Bidair, Kenneth Goldberg, Neal D. Shore, Susan Kalota, Ronald F. Tutrone, Jonathan I. Epstein, Steven A. Kaplan

Publikováno v: World Journal of Urology

Purpose This study was undertaken to determine the safety and efficacy of fexapotide triflutate (FT) 2.5 mg and 15 mg for the treatment of Grade Group 1 prostate cancer. Methods Prospective randomized transrectal intraprostatic single injection FT 2.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::102437b4f82242dfe77ce6634378349a
https://doi.org/10.1007/s00345-020-03127-w

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Autor: Renato D. Lopes, Celestia S. Higano, Susan F. Slovin, Adam J. Nelson, Robert Bigelow, Per S. Sørensen, Chiara Melloni, Shaun G. Goodman, Christopher P. Evans, Jan Nilsson, Deepak L. Bhatt, Noel W. Clarke, Tine K. Olesen, Belinda T. Doyle-Olsen, Henriette Kristensen, Lauren Arney, Matthew T. Roe, John H. Alexander, Mirjam Mol-Arts, Samreen Mansor-Lefebvre, Konstantin Zubovskiy, Allan Blemings, Klaus Dugi, Gerald Bloomfield, Chris Kontos, Adam DeVore, Dedrick Jordan, Bradley Kolls, Robin Matthews, Rajendra Mehta, Thomas J. Povsic, Michael Morse, Kenneth W. Mahaffey, Susan Halabi, Darryl Leong, Laurence Klotz, Neil Fleshner, Godfrey Jansz, Jonathan Giddens, Russell Egerdie, Joseph Chin, Joseph Zadra, Richard Casey, Jean Simard, Tamim Niazi, André-Guy Martin, Marek Babjuk, Jaroslav Hajek, Jiri Klecka, Jiri Kubes, Jan Schraml, Jitka Jakesova, Jaroslav Vanasek, Bohuslav Melichar, Heikki Seikkula, Manouar Samir Abdiche, Marc Colombel, Philippe Debourdeau, Gregoire Robert, Arnauld Villers, Guillaume Ploussard, Benjamin Pradere, Franck Bruyere, Jean-Luc Descotes, Idir Ouzaid, Alexander Winter, Herbert Hanitzsch, Herbert Sperling, Ralf Eckert, Peter Hammerer, Elke Stagge, Florian Seseke, Silvio Szymula, Aristotelis Bamias, Anastasios Thanos, Konstantinos Hatzimouratidis, Charalambos Mamoulakis, Haralabos Kalofonos, Elzbieta Oszukowska, Katarzyna Madziarska, Jacek Fijuth, Mateusz Obarzanowski, Boris Alekseev, Vagif Atduev, Dmitri Pushkar, Evgeniy Veliev, Alexander Zyryanov, Sergey Petrov, Evgeny Kopyltsov, Vadim Kozlov, Ladislav Macko, Jozef Dubravicky, Richard Polak, Obaidullah Mir, Marek Vargovcak, Ivan Mincik, Jan Kliment, Frederico Goncalves, Juraj Mikulas, Roman Sokol, Michal Korcek, Jozef Marko, Viktor Kovacik, Igor Milichovsky, Pavol Dubinsky, John Lazarus, Sanjay Dixit, Euan Green, Rajaguru Srinivasan, Danish Mazhar, Yeung Ng, Naveed Sarwar, Craig Herman, Frederick Snoy, Robert Given, Ronald Suh, David Lipsitz, James Bailen, Lawrence Gervasi, Idalia Acosta, Laurence Belkoff, Ning Wu, Jeffrey Frankel, Lawrence Karsh, Bryant Poole, David Lieber, Jason Engel, Mohamed Bidair, Steven Rosenberg, Paul Sieber, Adam Perzin, Susan Kalota, Amar Singh, Ralph Henderson, Jeffrey Wayne, Moben Mirza, Richard D’Anna, Fredrick Wolk, Osvaldo Padron, Kathryn Bylow, Jonathan Rubenstein, Benjamin Gartrell, Michael Schwartz, Kalpesh Patel, Ajit Maniam, Thomas Keane, Michael Goodman, Charles Bane, Michael Chung, Stephen Savage, Edward Uchio, Son Nguyen, William Aronson, Rakesh Khanna, Carlton Barnswell

Publikováno v: Circulation. 144(16)

Background: The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial. Methods: In this inter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd9271ccb4eb75e7486635b0056df019
https://pubmed.ncbi.nlm.nih.gov/35312383

Three‐month primary efficacy data for the SUCCESS Trial; a phase III, multi‐center, prospective, randomized, controlled study treating female stress urinary incontinence with the vesair intravesical balloon

Autor: Jeffrey A. Snyder, Susan Kalota, Karny Jacoby, Kaiser Robertson, Kevin Cline, Randall Kahan, Lonny Green, Kurt A. McCammon, Eric S. Rovner, Jack M. Zuckerman, Charles R. Rardin

Publikováno v: Neurourology and Urodynamics. 37:440-448

Aims The SUCCESS trial is a phase III study of the Vesair® balloon in the United States for female stress urinary incontinence (SUI). The purpose of this manuscript is to present the 3 month primary efficacy and tolerability outcome data. Methods Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81a8e6051e6dced5267c5d13cc3d3055
https://doi.org/10.1002/nau.23324

Prevention of Acrolein-Induced Bladder Injury by Pentosanpolysulfate

Autor: Susan Kalota, Paul C. Stein, C. Lowell Parsons

Publikováno v: Journal of Urology. 148:163-166

The active metabolite of cyclophosphamide, acrolein, which is capable of damaging the transitional epithelium of the bladder, was evaluated in both in vivo and in vitro models to determine if its damaging effect could be reduced by the presence of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb99267a1bc1480df13c4736a069311
https://doi.org/10.1016/s0022-5347(17)36545-x